BioNexus Gene Lab Corp.
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. BioNexus Gene Lab Corp.'s past years’ income statements indicate that its last revenue has decreased compared to the previous period by 11% to $9,770,806. Profit margin reached -27%. Total operating expenses were $3,923,086.

Profit Margin

BioNexus Gene Lab Corp. (NASDAQ:BGLC): Profit margin
2017 107.68K -123.75K -114.92%
2018 212.32K 26.45K 12.46%
2019 126.95K -246.46K -194.14%
2020 11.39M 1.09M 9.61%
2021 13.36M 751.57K 5.62%
2022 10.92M -355.96K -3.26%
2023 9.77M -2.62M -26.91%

BGLC Income Statement (2017 – 2023)

2023 2022 2021 2020 2019 2018 2017
Revenue
Revenue
9.77M10.92M13.36M11.39M126.95K212.32K107.68K
Cost of revenue
8.44M9.66M11.16M9.67M71.06K183.56K28.87K
Gross profit
1.32M1.25M2.19M1.71M55.88K28.76K78.80K
Operating exp.
Research and development
0000000
Selling and marketing
0000000
Total operating expenses
3.92M1.55M1.13M446.00K331.59K-31.13K206.71K
Operating income
-2.59M-291.17K1.05M1.27M-275.70K59.90K-127.91K
Other income (expenses), net
-13.92K-12.47K-12.97K-11.31K25.04K273.06K0
Income before tax
-2.60M-303.65K1.04M1.26M-275.70K59.90K-119.41K
Income tax expense
21.52K52.31K291.28K168.41K-29.23K33.44K4.33K
Net income
-2.62M-355.96K751.57K1.09M-246.46K26.45K-123.75K
Earnings per share
Basic EPS
-0.17-0.020.050.13-0.030.00-0.01
Diluted EPS
-0.17-0.020.050.13-0.030.00-0.01
Data sourceData sourceData sourceData sourceData source